$SHCR At $10 a share this company took advantage of crazy valuations SPACS are willing to pay for decent companies. Insiders sold a bunch of stock on the merger at a price North of $3.8 Billion ($10 a share). The shorts and other investors used the public liquidity to sell the stock down to $6.45 or close to a $2.7 Billion valuation less cash on balance sheet of $400. $2.3 Billion for $31 Million in 2021 EBITDA Still crazy expensive. The good news is that the company should grow EBITDA quickly to $100 and the stock can grow into its valuation. Probably a good place to start accumulating some stock if you have a long term perspective.
27
4
@JeffArnoldsGlasses @johns45 there’s an chance that it hits $5, as the inflationary/macro environment could bring it down. But that’s just short term price action. If your horizon is 1+ year and you got in below 7, it should be easy returns over the next few years. These type of companies don’t go unnoticed for too long. Lot of de-SPAC’d companies got hit hard after de-SPAC’ing. You just gotta be patient and hope the analysts come through. We need a few more of the big reputable ones. They haven’t even had their first ER call yet and no released financials as a public company. So this is probably not even popping up on most screens.
1
  • $SHCR At $10 a share this company took advantage of crazy valuations SPACS are willing to pay for decent companies. Insiders sold a bunch of stock on the merger at a price North of $3.8 Billion ($10 a share). The shorts and other investors used the public liquidity to sell the stock down to $6.45 or close to a $2.7 Billion valuation less cash on balance sheet of $400. $2.3 Billion for $31 Million in 2021 EBITDA Still crazy expensive. The good news is that the company should grow EBITDA quickly to $100 and the stock can grow into its valuation. Probably a good place to start accumulating some stock if you have a long term perspective.
    27
    4
  • @JeffArnoldsGlasses @johns45, I have no idea where John is getting his PT. These companies get valued on EV/rev usually, not EBITDA or PE. Healthcare tech and disruption stocks typically get a ‘21 EV/rev of 10-15 easily (e.g. $TDOC $GDRX $PHR, and etc.), for this type of revenue growth. Their current ‘21 EV/rev is ~5 right now…it is just an added bonus that they are EBITDA positive, as most are not. If you believe their ‘22 projections, they are even more behind in peer multiples.
    2
  • @JeffArnoldsGlasses @johns45 there’s an chance that it hits $5, as the inflationary/macro environment could bring it down. But that’s just short term price action. If your horizon is 1+ year and you got in below 7, it should be easy returns over the next few years. These type of companies don’t go unnoticed for too long. Lot of de-SPAC’d companies got hit hard after de-SPAC’ing. You just gotta be patient and hope the analysts come through. We need a few more of the big reputable ones. They haven’t even had their first ER call yet and no released financials as a public company. So this is probably not even popping up on most screens.
    1
  • @johns45 show me were insiders sold though.... have you even read any of the filings or just making assumptions? Insider shares are locked up for 6months or 12.50 for like 20days I assume what you are calling insider sells were fcac shares being converted over to sharecare shares, might want to double check that Majority of the float is owned by insiders and tutes, since despac it has avg. Atleast 50%+ short volume This is more of pipe investors hedging their bet.
  • @JeffArnoldsGlasses @johns45, here is a high level comparison, as of Friday close, between some of the top healthcare tech/disruptors. All revenue projections are from consensus (or company's guidance). $SHCR is on the low end and arguably undervalued, as their revenue growth is on the high end. Amwell used to be on TDOC's level, but got hammered recently. Most of its peers are also not EBITDA positive either. And yes, I'm also invested in $UPH and $DRIO, lol
  • @penuschrist Some Sharecare shareholders received $10 a share on the closing of the merger as they decided to sell shares on the closing. Read the prospectus outlining the transaction. They have been in the deal for a while so cant blame them..plus the great valuation.
  • @JeffArnoldsGlasses The stock price is speaking volumes right now. Analyst coverage will not change the valuation. Im sure there will be some undisciplined analysts that will give it a high price but right now the market is awash in overpriced small and midcap stocks. In three years they will do $100 million in EBITDA......give it whatever multiple you want. Im buying stock down here but expecting lower prices.
  • @johns45 ok that's typical with any spac, you have a chance to redeem for original price it was listed if you dont like the merger or just want to exit, and those are fcac(the spac) shares it's not
  • @johns45 they converted fcac shares to sharecare Example from one of the filings, 20,000class b fcac shares disposed of (indicated by the D in the box) and converted to 20,000 class A shares of sharecare(acquired indicated by the A in the box) Easy mistake just gotta pay close attention to filings, the only shares that actually went anywhere were a few million donated to charity
  • @penuschrist Shareholders of Sharecare SOLD Stock as part of the merger with the SPAC its detailed in the prospectus..read it. $275 million worth at $10...do your homework. The goodnews is that it was only 7% of mkt cap.
  • @johns45 ok so as I said it wasent insiders, and if pre public equity holders sold 27.5mm shares where did they go? It wasent on the open market we haven't even had 27.5mm volume total since merger completion
  • @johns45 they didnt dump shares though, that was part of the deal for fcac to buy the equity of pre public sharecare. Equity holders got up to 275mm in cash consideration and shcr stock That's been inked in since merger was announced That's like saying shcr insiders sold $401mm worth becuase shcr got $401mm @ closing
  • @penuschrist This is pretty simple. Shareholders in Sharecare chose to sell 27.5 million shares of their holdings at $10 a share as part of the merger. Some of them had been investors for many years and wanted to free up capital. Others did not want to wait for the lockup to expire 6 months after. Whatever the reasons 7% of existing shareholders sold their stock on the merger the rest converted to SHCR stock. Case closed. Go buy more stock its only expensive now.
  • @johns45 yes but those shares went to fcac and pipe investors, else they would have diluted existing equity holders or pre public sharecare. Your original comment that this all started from worded it in a way like sharecare insiders sold 27.5m shares of $SHCR This is standard practice for all spacs how else do pipe investors and the spac get their percentage of equity in the surviving company, nothing was sold on the open market it was transferred to new investors Theres a reason the public float is less than 10% of the total float